أعرض في EDS

Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) from the KarMMa Study

التفاصيل البيبلوغرافية
العنوان:	Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) from the KarMMa Study
المؤلفون:	Nikhil C. Munshi, Jesús San-Miguel, Larry D. Anderson Jr., Sagar Lonial, Anna Truppel-Hartmann, Jill Sanford, Everton Rowe, Timothy B. Campbell, Paula Rodriguez-Otero
المصدر:	Transplantation and Cellular Therapy. 28:S171
بيانات النشر:	Elsevier BV, 2022.
سنة النشر:	2022
مصطلحات موضوعية:	Transplantation, Molecular Medicine, Immunology and Allergy, Cell Biology, Hematology
تدمد:	2666-6367
DOI:	10.1016/s2666-6367(22)00372-4
URL الوصول:	https://explore.openaire.eu/search/publication?articleId=doi_________::1a2310d07ad36efb59abaa7e085dbfa1 https://doi.org/10.1016/s2666-6367(22)00372-4
Rights:	OPEN
رقم الانضمام:	edsair.doi...........1a2310d07ad36efb59abaa7e085dbfa1
قاعدة البيانات:	OpenAIRE

الوصف
تدمد:	26666367
DOI:	10.1016/s2666-6367(22)00372-4